Pakpoom Tantrachoti, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1164833810
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,599 of the $5,296 with a category attached, or 67.9%. 18 manufacturers reported payments, led by Abbott at 47.0% of the total. Reporting peaked in 2023 at $2,340 and has fallen 77.1% since, to $535 in 2025.
Across 102 payments — averaging $51.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$916
- AstraZeneca$290
- Alnylam Pharmaceuticals Inc.$273
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$261
- Impulse Dynamics (USA) Inc.$242
- plus $828 from 12 others
What the payments were for
- Travel & lodging$1,51029%
- Food & beverage$3,59968%
- Education$1884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $2,488 |
| Abiomed | 5 | $916 |
| AstraZeneca | 6 | $290 |
| Alnylam Pharmaceuticals Inc. | 8 | $273 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $261 |
| Impulse Dynamics (USA) Inc. | 7 | $242 |
| E.r. Squibb & Sons, L.L.C. | 8 | $152 |
| Merck | 4 | $127 |
| Atricure, Inc. | 1 | $116 |
| Pfizer | 6 | $113 |
| Novartis | 6 | $103 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| Edwards Lifesciences | 1 | $45 |
| Kestra Medical Technology Services, Inc. | 1 | $31 |
| Amgen | 1 | $21 |
| Cvrx, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,296 in reported general payments places this provider in the 65th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 270 | $289,852 |
| CamzyosMavacamten | 27 | $221,339 |
| JardianceEmpagliflozin | 125 | $88,118 |
| FarxigaDapagliflozin Propanediol | 85 | $63,499 |
| EliquisApixaban | 61 | $56,025 |
| CorlanorIvabradine Hcl | 12 | $7,401 |
| Potassium Chloride | 133 | $4,156 |
| Torsemide | 105 | $3,997 |
| Metoprolol Succinate | 191 | $3,654 |
| Spironolactone | 187 | $1,468 |
| Carvedilol | 142 | $1,343 |
| Tacrolimus | 11 | $1,317 |
| Ranolazine ErRanolazine | 19 | $1,210 |
| Hydralazine Hcl | 35 | $1,159 |
| Eplerenone | 29 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $103 | $289,852270 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $152 | $221,33927 claims |
| AstraZenecaFarxiga | $290 | $63,49985 claims |
| PfizerEliquis | $113 | $56,02561 claims |
| AmgenCorlanor | $21 | $7,40112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Reji PappyOklahoma City$25K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Vinodh JeevananthamOklahoma City$11K
- Niraj PrasadOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.